Endogenous Metabolite (EM) Information
| Endogenous Metabolite (EM) Information | ||||||
|---|---|---|---|---|---|---|
| EM ID |
EM00159
|
|||||
| EM Name |
Prostaglandin F2 alpha
|
|||||
| Synonyms |
dinoprost; prostaglandin F2alpha; PGF2alpha; Prostaglandin F2a; amoglandin; Enzaprost; Cerviprost; Enzaprost F; panacelan; Protamodin; l-PGF2-alpha; l-Prostaglandin F2-alpha; Dinoprostum; Dinoprosta; Prostin F2alpha; cyclosin; Prostin F2-alpha; PGF2 alpha; PGF-2alpha; PGF2-alpha; Prostarmon F; Prostaglandin F2-alpha; Prostaglandin F2 alpha; 9alpha,11alpha-PGF2; PGF2; Prostaglandin F(sub 2a); Dinoprostum [INN-Latin]; Dinoprosta [INN-Spanish]; UNII-B7IN85G1HY; CCRIS 4253; U-14583; U 14583; Prostaglandin F2; HSDB 3315
|
|||||
| Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5280363"></iframe>
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C20H34O5
|
|||||
| Canonical SMILES |
CCCCCC(C=CC1C(CC(C1CC=CCCCC(=O)O)O)O)O
|
|||||
| InChI |
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1
|
|||||
| InChIKey |
PXGPLTODNUVGFL-YNNPMVKQSA-N
|
|||||
| CAS Number |
CAS 551-11-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 354.5 | Topological Polar Surface Area | 98 | ||
| Heavy Atom Count | 25 | Rotatable Bond Count | 12 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
2.7
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:15553
|
|||||
| DT(s) "handling" This EM | OCT-1 | Transporter Info | Organic cation transporter 1 | [1] | ||
| OCT-2 | Transporter Info | Organic cation transporter 2 | [2] | |||
| References | ||||||
| 1 | Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8. | |||||
| 2 | Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.